» Articles » PMID: 31832232

Therapeutic Efficacy of Nanoparticles and Routes of Administration

Overview
Journal Biomater Res
Date 2019 Dec 14
PMID 31832232
Citations 273
Authors
Affiliations
Soon will be listed here.
Abstract

In modern-day medicine, nanotechnology and nanoparticles are some of the indispensable tools in disease monitoring and therapy. The term "nanomaterials" describes materials with nanoscale dimensions (< 100 nm) and are broadly classified into natural and synthetic nanomaterials. However, "engineered" nanomaterials have received significant attention due to their versatility. Although enormous strides have been made in research and development in the field of nanotechnology, it is often confusing for beginners to make an informed choice regarding the nanocarrier system and its potential applications. Hence, in this review, we have endeavored to briefly explain the most commonly used nanomaterials, their core properties and how surface functionalization would facilitate competent delivery of drugs or therapeutic molecules. Similarly, the suitability of carbon-based nanomaterials like CNT and QD has been discussed for targeted drug delivery and siRNA therapy. One of the biggest challenges in the formulation of drug delivery systems is fulfilling targeted/specific drug delivery, controlling drug release and preventing opsonization. Thus, a different mechanism of drug targeting, the role of suitable drug-laden nanocarrier fabrication and methods to augment drug solubility and bioavailability are discussed. Additionally, different routes of nanocarrier administration are discussed to provide greater understanding of the biological and other barriers and their impact on drug transport. The overall aim of this article is to facilitate straightforward perception of nanocarrier design, routes of various nanoparticle administration and the challenges associated with each drug delivery method.

Citing Articles

Revolutionizing Nanovaccines: A New Era of Immunization.

Saleh M, El-Moghazy A, Elgohary A, Saber W, Helmy Y Vaccines (Basel). 2025; 13(2).

PMID: 40006673 PMC: 11860605. DOI: 10.3390/vaccines13020126.


Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.

Yang H, Li J, Song C, Li H, Luo Q, Chen M Int J Mol Sci. 2025; 26(4).

PMID: 40004206 PMC: 11855571. DOI: 10.3390/ijms26041743.


Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.

Reddi Sree R, Kalyan M, Anand N, Mani S, Gorantla V, Sakharkar M ACS Omega. 2025; 10(6):5148-5171.

PMID: 39989768 PMC: 11840625. DOI: 10.1021/acsomega.4c05527.


Systematic review of peptide nanoparticles for improved diabetes outcomes: insights and opportunities.

Dangana R, Okon M, Orire I, Sanusi I, Terkimbi S, Aja P Discov Nano. 2025; 20(1):41.

PMID: 39961878 PMC: 11832960. DOI: 10.1186/s11671-025-04215-9.


Innovative approaches to asthma treatment: harnessing nanoparticle technology.

Goswami V, Sodhi K, Singh C Discov Nano. 2025; 20(1):21.

PMID: 39922940 PMC: 11807046. DOI: 10.1186/s11671-025-04211-z.


References
1.
Lu J, Wang X, Marin-Muller C, Wang H, Lin P, Yao Q . Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009; 9(4):325-41. PMC: 2701163. DOI: 10.1586/erm.09.15. View

2.
Hwang S, Kim K . Nano-enabled delivery systems across the blood-brain barrier. Arch Pharm Res. 2013; 37(1):24-30. DOI: 10.1007/s12272-013-0272-6. View

3.
Gao H, Pang Z, Jiang X . Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res. 2013; 30(10):2485-98. DOI: 10.1007/s11095-013-1122-4. View

4.
Decuzzi P, Pasqualini R, Arap W, Ferrari M . Intravascular delivery of particulate systems: does geometry really matter?. Pharm Res. 2008; 26(1):235-43. DOI: 10.1007/s11095-008-9697-x. View

5.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View